Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.65+0.01 (+1.31%)
Close on Nov 12, 2026Market cap $255.73MP/E 3.0Yield –
Standard BioTools r&d expenses
Research and development expenses are spending on new products and technology.
Standard BioTools's R&D Expenses for the twelve months ending Jun 30, 2026 was $18.42M, down 28.2% year over year. For fiscal 2025 it was $25.99M, down 9.9% from the year before. Over ten years it grew -4.0% a year on average. The highest annual figure on record is $43.42M in fiscal 2014.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.99M | -9.9% |
| FY2024 | Dec 31, 2024 | $28.83M | +11.1% |
| FY2023 | Dec 31, 2023 | $25.95M | -30.6% |
| FY2022 | Dec 31, 2022 | $37.38M | -1.5% |
| FY2021 | Dec 31, 2021 | $37.94M | +4.1% |
| FY2020 | Dec 31, 2020 | $36.46M | +15.2% |
| FY2019 | Dec 31, 2019 | $31.64M | +5.4% |
| FY2018 | Dec 31, 2018 | $30.03M | -2.6% |
| FY2017 | Dec 31, 2017 | $30.83M | -19.8% |
| FY2016 | Dec 31, 2016 | $38.42M | -2.2% |
| FY2015 | Dec 31, 2015 | $39.26M | -9.6% |
| FY2014 | Dec 31, 2014 | $43.42M | +117.6% |
| FY2013 | Dec 31, 2013 | $19.95M | +20.2% |
| FY2012 | Dec 31, 2012 | $16.60M | +19.1% |
| FY2011 | Dec 31, 2011 | $13.94M | +7.1% |
| FY2010 | Dec 31, 2010 | $13.01M | +5.6% |
| FY2009 | Dec 31, 2009 | $12.32M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.98M | -68.2% |
| Q1 FY2026 | Mar 31, 2026 | $2.12M | -61.1% |
| Q4 FY2025 | Dec 31, 2025 | $7.97M | +13.2% |
| Q3 FY2025 | Sep 30, 2025 | $6.36M | -8.4% |
| Q2 FY2025 | Jun 30, 2025 | $6.22M | -14.1% |
| Q1 FY2025 | Mar 31, 2025 | $5.44M | -66.0% |
| Q4 FY2024 | Dec 31, 2024 | $7.04M | +1.9% |
| Q3 FY2024 | Sep 30, 2024 | $6.94M | +8.9% |
| Q2 FY2024 | Jun 30, 2024 | $7.24M | +17.1% |
| Q1 FY2024 | Mar 31, 2024 | $15.98M | +148.6% |
| Q4 FY2023 | Dec 31, 2023 | $6.91M | -6.9% |
| Q3 FY2023 | Sep 30, 2023 | $6.37M | -24.9% |
| Q2 FY2023 | Jun 30, 2023 | $6.18M | -50.9% |
| Q1 FY2023 | Mar 31, 2023 | $6.43M | -27.5% |
| Q4 FY2022 | Dec 31, 2022 | $7.43M | -13.1% |
| Q3 FY2022 | Sep 30, 2022 | $8.49M | -7.9% |
| Q2 FY2022 | Jun 30, 2022 | $12.61M | +33.5% |
| Q1 FY2022 | Mar 31, 2022 | $8.87M | -17.6% |
| Q4 FY2021 | Dec 31, 2021 | $8.54M | -23.6% |
| Q3 FY2021 | Sep 30, 2021 | $9.21M | +13.3% |
| Q2 FY2021 | Jun 30, 2021 | $9.44M | +11.8% |
| Q1 FY2021 | Mar 31, 2021 | $10.75M | +23.6% |
| Q4 FY2020 | Dec 31, 2020 | $11.19M | +35.1% |
| Q3 FY2020 | Sep 30, 2020 | $8.13M | +14.1% |
| Q2 FY2020 | Jun 30, 2020 | $8.45M | +7.4% |
| Q1 FY2020 | Mar 31, 2020 | $8.70M | +3.9% |
| Q4 FY2019 | Dec 31, 2019 | $8.28M | +4.0% |
| Q3 FY2019 | Sep 30, 2019 | $7.13M | -4.1% |
| Q2 FY2019 | Jun 30, 2019 | $7.87M | +6.5% |
| Q1 FY2019 | Mar 31, 2019 | $8.37M | +15.4% |
| Q4 FY2018 | Dec 31, 2018 | $7.96M | +11.2% |
| Q3 FY2018 | Sep 30, 2018 | $7.43M | -3.3% |
| Q2 FY2018 | Jun 30, 2018 | $7.39M | -1.0% |
| Q1 FY2018 | Mar 31, 2018 | $7.26M | -14.9% |
| Q4 FY2017 | Dec 31, 2017 | $7.16M | -18.4% |
| Q3 FY2017 | Sep 30, 2017 | $7.68M | -17.0% |
| Q2 FY2017 | Jun 30, 2017 | $7.46M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.52M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.77M | – |
| Q3 FY2016 | Sep 30, 2016 | $9.25M | – |
See a number that looks wrong?